We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
+4.29%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
AUM
$20.7B
AUM Growth
-$166M
Cap. Flow
-$582M
Cap. Flow %
-2.82%
Top 10 Hldgs %
30.44%
Holding
2,896
New
52
Increased
415
Reduced
1,909
Closed
89

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.1M
2
AAPL icon
Apple
AAPL
+$58M
3
MSFT icon
Microsoft
MSFT
+$49.2M
4
EFA icon
iShares MSCI EAFE ETF
EFA
+$25.9M
5
AL
Air Lease Corp
AL
+$21.6M

Sector Composition

Rank Sector Weight
1 Technology 30.28%
2 Financials 13.29%
3 Healthcare 10.43%
4 Consumer Discretionary 10.39%
5 Industrials 9.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACN icon
76
Accenture
ACN
$110B
$39.9M 0.19%
148,759
-5,835
-4% -$1.48M
INTC icon
77
Intel
INTC
$509B
$39.6M 0.19%
1,073,712
-12,189
-1% -$460K
ANET icon
78
Arista Networks
ANET
$265B
$39M 0.19%
297,268
-7,312
-2% -$1.01M
SPGI icon
79
S&P Global
SPGI
$121B
$38.8M 0.19%
74,203
-3,244
-4% -$1.61M
GILD icon
80
Gilead Sciences
GILD
$168B
$38.5M 0.19%
313,663
-10,154
-3% -$1.23M
BLK icon
81
Blackrock
BLK
$180B
$37.2M 0.18%
34,727
-1,151
-3% -$1.26M
COF icon
82
Capital One
COF
$136B
$36.9M 0.18%
152,284
-6,206
-4% -$1.38M
PANW icon
83
Palo Alto Networks
PANW
$315B
$36.1M 0.17%
196,143
-502
-0.3% -$101K
BSX icon
84
Boston Scientific
BSX
$74.5B
$35M 0.17%
367,541
-12,062
-3% -$1.18M
DHR icon
85
Danaher
DHR
$145B
$34.5M 0.17%
150,720
-7,413
-5% -$1.63M
WELL icon
86
Welltower
WELL
$166B
$34.1M 0.16%
183,644
-1,030
-0.6% -$192K
PFE icon
87
Pfizer
PFE
$150B
$33.9M 0.16%
1,362,930
-47,688
-3% -$1.2M
CRWD icon
88
CrowdStrike
CRWD
$226B
$33.8M 0.16%
288,096
-5,204
-2% -$663K
UNP icon
89
Union Pacific
UNP
$174B
$33.4M 0.16%
144,552
-4,909
-3% -$1.12M
VRTX icon
90
Vertex Pharmaceuticals
VRTX
$133B
$33.2M 0.16%
73,281
-2,526
-3% -$1.09M
BX icon
91
Blackstone
BX
$110B
$32.8M 0.16%
212,842
-4,613
-2% -$701K
LOW icon
92
Lowe's Companies
LOW
$121B
$32.4M 0.16%
134,438
-4,617
-3% -$1.11M
PGR icon
93
Progressive
PGR
$121B
$32.3M 0.16%
141,985
-4,853
-3% -$1.1M
ADI icon
94
Analog Devices
ADI
$187B
$32M 0.15%
118,003
-5,122
-4% -$1.29M
PLD icon
95
Prologis
PLD
$134B
$31.7M 0.15%
248,489
-7,748
-3% -$966K
MDY icon
96
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27.2B
$31.6M 0.15%
52,300
+29,000
+124% +$17.4M
SYK icon
97
Stryker
SYK
$133B
$30.5M 0.15%
86,779
-2,788
-3% -$1.02M
AXSM icon
98
Axsome Therapeutics
AXSM
$11.2B
$30.1M 0.15%
164,871
-32,447
-16% -$4.53M
HON icon
99
Honeywell
HON
$74.6B
$29.7M 0.14%
152,214
-14,942
-9% -$2.92M
ETN icon
100
Eaton
ETN
$179B
$29.7M 0.14%
93,166
-3,471
-4% -$1.23M

Similar funds

MetLife Investment Management's Q4 2025 Portfolio in Review

As of Q4 2025, MetLife Investment Management held 2,896 positions worth $20.7B, down 0.8% from $20.8B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Trading was light in Q4 2025: portfolio turnover was 4.9%. MetLife Investment Management opened 52 new positions and exited 89, leaving the 2,896-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 31% a quarter earlier, followed by Financials and Healthcare.

  • MetLife Investment Management's largest Q4 2025 buy was RTX Corp: 321,368 shares worth $58.9M.
  • MetLife Investment Management added most to State Street SPDR S&P 500 ETF Trust in Q4 2025, an estimated $54.6M increase.
  • MetLife Investment Management's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $65.1M.
  • MetLife Investment Management fully exited Kellanova in Q4 2025, selling an estimated $5.48M.
  • MetLife Investment Management's ten largest holdings make up 30% of its $20.7B portfolio in Q4 2025.
  • MetLife Investment Management opened 52 new positions and closed 89 in Q4 2025.
  • MetLife Investment Management's portfolio value fell 0.8% quarter-over-quarter to $20.7B.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.